Five specialty pharmaceutical trends to watchApprovals of specialty pharmaceuticals have far outpaced traditional drugs, and that trend will continue. But that’s not the only specialty medication trend that healthcare executives should have on their radar.
Risk of neutropenia prompts new monitoring for antipsychotic drugFDA announced new requirements for the monitoring, prescribing, and dispensing of clozapine, an atypical antipsychotic for treatment-resistant schizophrenia, due to the continued risk of severe neutropenia, which can be life-threatening.
FDA’s First Biosimilar Approval Draws Excitement, ConcernThe FDA has approved filgrastim-sndz (Zarxio, Sandoz), treating patients at increased risk of neutropenia, but it's stirring up mixed emotions. Learn why
Fast antibiotics reduce PICU needs, mortality of pediatric cancer patientsPediatric cancer patients who receive antibiotics within 60 minutes of reporting fever and showing neutropenia (low neutrophil count), go on to have decreased intensive care needs and lower mortality compared with patients who receive antibiotics outside the 60-minute window, according to a University of Colorado Cancer Center study published in Pediatric Blood & Cancer.
FDA drug approvals-January 2015FDA actions in brief, recommendations for approval, fast-track designations.
Cholesterol-lowering agent leads list of most-prescribed drugsRosuvastatin (Crestor, AstraZeneca), a cholesterol-lowering agent, is currently the most-prescribed drug among the 100 most-prescribed and best-selling drugs in the United States. In the past 12 months, new prescriptions and refills for rosuvastatin have been estimated to amount to 23.7 million.